

# CONTENTS

<b>Certificate</b>	<b>i</b>
<b>Declaration</b>	<b>ii</b>
<b>Preface</b>	<b>iii</b>
<b>Acknowledgements</b>	<b>iv</b>
<b>1. Introduction</b>	<b>1</b>
1.1 Metabolic disorder	1
1.2 Currently marketed drugs for the treatment of metabolic disorder	8
1.3 Diagnosis and potential targets for the treatment of metabolic disorder	9
1.4 Dyslipidemia targets	13
1.5 Diabetes targets	14
1.6 Why PPARs ?	16
1.7 PPAR $\alpha$	20
1.8 PPAR $\gamma$	26
1.9 PPAR $\delta$	30
1.10 Concept of dual agonist of PPAR $\alpha/\gamma$	31
1.11 References	37
<b>2 Design, synthesis and biological evaluation of PPAR<math>\alpha/\gamma</math>     dual agonists</b>	<b>51</b>
2.1 Common structural features of PPAR agonists	51
2.2 Novel PPAR dual agonists	52
2.3 Summary of chapter 2	93
2.4 References	96

<b>3.</b>	<b>Experimental</b>	<b>100</b>
3.1	Synthesis of phenylpropane derivatives	101
3.2	Synthesis oxybenzylglycine derivatives	117
3.3	Synthesis of thiophene substituted oxazoles one carbon linker chain analogues	137
3.4	Synthesis of thiophene substituted oxazoles two carbon linker chain analogues	168
3.5	<i>in vitro</i> PPAR transactivation assay	208
3.6	<i>in vivo</i> experiments	209
3.7	Pharmacokinetics experiment	210
3.8	References	213
<b>4</b>	<b>Spectra</b>	<b>214</b>
<b>5</b>	<b>Publications</b>	<b>308</b>
<b>6</b>	<b>Vitae</b>	<b>322</b>